SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Fredun Pharmaceuticals moves up as its arm acquires controlling interest in One Pet Stop

01 Jul 2025 Evaluate

Fredun Pharmaceuticals is currently trading at Rs. 837.75, up by 7.30 points or 0.88% from its previous closing of Rs. 830.45 on the BSE.

The scrip opened at Rs. 844.90 and has touched a high and low of Rs. 844.90 and Rs. 830.05 respectively. So far 2422 shares were traded on the counter.

The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 904.00 on 30-Jul-2024 and a 52 week low of Rs. 635.00 on 16-Jan-2025.

Last one week high and low of the scrip stood at Rs. 844.90 and Rs. 796.00 respectively. The current market cap of the company is Rs. 395.68 crore.

The promoters holding in the company stood at 48.93%, while Institutions and Non-Institutions held 1.59% and 49.48% respectively. 

Fredun Pharmaceuticals’ (FPL) wholly owned subsidiary -- Fredun Retail (FRPL) has taken a significant step toward expanding its consumer-centric portfolio with the acquisition of a controlling interest in One Pet Stop.

This acquisition marks FPL’s formal entry into the organized pet care services market and aligns with its long-term vision of becoming a holistic healthcare provider across human and animal wellness domains. 

With this acquisition, Fredun gains access to a loyal and recurring customer base of over 4,000 pet owners, reflecting One Pet Stop’s established brand equity and trust in the pet care space. One Pet Shop has built a consumer-first business model focused on personalized service, reliability, and convenience. Its user-friendly mobile app allows pet owners to book pet grooming services, track appointments, and receive timely healthcare reminders, thereby fostering long-term customer engagement. 

The acquisition creates strong synergies with Fredun’s Freossi brand, which offers a premium range of pet grooming products. By combining One Pet Stop’s B2C service delivery model with Fredun’s manufacturing capabilities and pan-India distribution network, the Group is poised to expand aggressively across high-consumption zones, particularly within the MMRDA region and other major urban markets. 

Fredun Pharmaceuticals is engaged in manufacturing of pharmaceutical products.

Fredun Pharma Share Price

2043.90 -23.80 (-1.15%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×